Articles by Andrew Moreno
Adrián Mosquera Orgueira, MD, PhD, spoke of his team's study into machine learning tools for improving risk stratification.
The Clinical Practice Guidance document issued by the EHA, ISTH, EAHAD, and ESO addresses both hemophilia A and B.
Malignant neoplasm-associated hemophagocytic lymphohistiocytosis, COVID-19, and CAR T-cell therapy can each initiate CS.
In a phase 1 trial the product performed favorably in aplastic anemia, myelofibrosis, and hypoplastic myelodysplasia.
The reduced-dose oral regimen also had lower incidence of clinically relevant bleeding complications and mortality rate.
The platform features incubation technology able to replicate cell microenvironments associated with SCD sickling.
ASH Awards Commitee Chair Ivan Maillard, MD, PhD, and prior awardee Rinku Majumder, PhD, tell of the Grant's positive impact.
The agent recalibrates the immune system to attack tumors and increases cancer susceptibility to standard of care therapy.
Investigational T-Cell Immunotherapy Superior to Standard HSCT in Rate of Survival Plus GvHD Freedom
A phase 3 study comparing the treatments in multiple hematologic malignancies also saw greater overall survival at one year.
Azercabtagene zapreleucel is an allogeneic CD-19-targeting therapy combining lymphodepletion chemotherapy with interleukin-2.
The hepcidin mimetic increased hematocrit control and reduced both phlebotomy need and symptoms in a phase 2 trial.
Thrombosis history was not predictive of overall survival in patients with pulmonary hypertension risk and PV, a study found.
The oral agent exhibited promising hemoglobin response performance and safety in this stage of an ongoing phase 2/3 study.
The first-in-class agent operates by increasing both von Willebrand factor and factor VIII levels in patients.
Immune thrombocytopenia featured most prominently at the Meeting but new data was presented for several forms of the disease.
In findings arterial thrombosis carried worse overall survival than venous thrombosis in this patient population.
Clinical trials are ongoing to evaluate this orally available, selective inhibitor of XPO1 as part of combination regimens.
The panel's discussion, moderated by Neil Love, MD, dove especially into the nuances of using avapritinib and ruxolitinib.
Neil Love, MD, has moderated an expert panel discussing current practice and recent data behind these treatments for NHL.
Anthony Sochet, MD, MS, on Knowledge Gaps Affecting Pediatric Inpatient Thromboprophylaxis Decisions
Clinical data is limited in areas such as how to evaluate bleeding risk and when to apply mechanical thromboprophylaxis.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.